Replies to post #29959 on Biotech Values

[north40000]

RPBIF, INSM

After our mutual, recent experience with INSM,
dare we try another? I have been watching RPBIF
go [un]steadily down for awhile now, but it becomes
tempting at $0.62.

I am especially irate with DNA seemingly using TRCA
[its mock David]as a well-planned strategic pawn in
its suit against INSM. My fond hope is that DNA fails
twice: its IGF-1 product and its law suit.